Ombitasvir (ABT-267), a novel NS5A inhibitor for the treatment of hepatitis C
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Ombitasvir (ABT-267), a novel NS5A inhibitor for the treatment of hepatitis C
Authors
Keywords
-
Journal
EXPERT OPINION ON PHARMACOTHERAPY
Volume 15, Issue 17, Pages 2609-2622
Publisher
Informa Healthcare
Online
2014-10-27
DOI
10.1517/14656566.2014.972364
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Hepatitis C Virus Genetic Variability and the Presence of NS5B Resistance-Associated Mutations as Natural Polymorphisms in Selected Genotypes Could Affect the Response to NS5B Inhibitors
- (2014) V. C. Di Maio et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Antiviral therapy of hepatitis C in 2014: Do we need resistance testing?
- (2014) Maximilian David Schneider et al. ANTIVIRAL RESEARCH
- Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection
- (2014) Hiromitsu Kumada et al. HEPATOLOGY
- A randomized, double-blind, multiple-dose study of the pan-genotypic NS5A inhibitor samatasvir in patients infected with hepatitis C virus genotype 1, 2, 3 or 4
- (2014) Bradley Vince et al. JOURNAL OF HEPATOLOGY
- Discovery of ABT-267, a Pan-Genotypic Inhibitor of HCV NS5A
- (2014) David A. DeGoey et al. JOURNAL OF MEDICINAL CHEMISTRY
- Strategies to manage hepatitis C virus (HCV) disease burden
- (2014) H. Wedemeyer et al. JOURNAL OF VIRAL HEPATITIS
- Determinants for Membrane Association of the Hepatitis C Virus NS2 Protease Domain
- (2014) C. M. Lange et al. JOURNAL OF VIROLOGY
- Retreatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin
- (2014) Stefan Zeuzem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Treatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin
- (2014) Jordan J. Feld et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection
- (2014) Nezam Afdhal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection
- (2014) Nezam Afdhal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
- (2014) Kris V. Kowdley et al. NEW ENGLAND JOURNAL OF MEDICINE
- Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection
- (2014) Mark S. Sulkowski et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase 2b Trial of Interferon-free Therapy for Hepatitis C Virus Genotype 1
- (2014) Kris V. Kowdley et al. NEW ENGLAND JOURNAL OF MEDICINE
- ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis
- (2014) Fred Poordad et al. NEW ENGLAND JOURNAL OF MEDICINE
- Persistence of Resistant Variants in Hepatitis C Virus-Infected Patients Treated with the NS5A Replication Complex Inhibitor Daclatasvir
- (2013) Chunfu Wang et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Simeprevir Increases Rate of Sustained Virologic Response Among Treatment-Experienced Patients With HCV Genotype-1 Infection: A Phase IIb Trial
- (2013) Stefan Zeuzem et al. GASTROENTEROLOGY
- Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: Updated criteria and genotype assignment web resource
- (2013) Donald B. Smith et al. HEPATOLOGY
- New horizons in hepatitis C antiviral therapy with direct-acting antivirals
- (2013) Alessio Aghemo et al. HEPATOLOGY
- NS5A inhibitors in the treatment of hepatitis C
- (2013) Jean-Michel Pawlotsky JOURNAL OF HEPATOLOGY
- Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders
- (2013) Anna S. Lok et al. JOURNAL OF HEPATOLOGY
- Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C
- (2013) Edward J. Gane et al. NEW ENGLAND JOURNAL OF MEDICINE
- Epidemiology of Viral Hepatitis and Hepatocellular Carcinoma
- (2012) Hashem B. El-Serag GASTROENTEROLOGY
- Correlation between NS5A Dimerization and Hepatitis C Virus Replication
- (2012) Precious J. Lim et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C
- (2011) Stefan Zeuzem et al. HEPATOLOGY
- Boceprevir for Untreated Chronic HCV Genotype 1 Infection
- (2011) Fred Poordad et al. NEW ENGLAND JOURNAL OF MEDICINE
- Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection
- (2011) Bruce R. Bacon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection
- (2011) Ira M. Jacobson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evolving epidemiology of hepatitis C virus
- (2010) D. Lavanchy CLINICAL MICROBIOLOGY AND INFECTION
- Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection
- (2010) Michael P. Manns et al. JOURNAL OF HEPATOLOGY
- Drug-drug interactions in the treatment of HIV infection: focus on pharmacokinetic enhancement through CYP3A inhibition
- (2010) F. Josephson JOURNAL OF INTERNAL MEDICINE
- Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect
- (2010) Min Gao et al. NATURE
- Rapid Emergence of Protease Inhibitor Resistance in Hepatitis C Virus
- (2010) L. Rong et al. Science Translational Medicine
- Domain 3 of non-structural protein 5A from hepatitis C virus is natively unfolded
- (2009) Xavier Hanoulle et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Molecular epidemiology of hepatitis C genotype 6a from patients with chronic hepatitis C from Hong Kong
- (2009) Cheryl S.Y. Li et al. JOURNAL OF MEDICAL VIROLOGY
- Crystal Structure of a Novel Dimeric Form of NS5A Domain I Protein from Hepatitis C Virus
- (2009) R. A. Love et al. JOURNAL OF VIROLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started